Riyaz Mohammed
Esani Diabetes and Mutlispeciality Research Centre, India
Title: Significance of Using Voglibose in IGT Patients
Biography
Biography: Riyaz Mohammed
Abstract
The increased prevalence of type 2 diabetes mellitus is a major concern for the health providers. We have done an observation study in the diagnosed IGT patient who received α-glucosidase inhibitor (voglibose), which could prevent the development of type 2 diabetes in high-risk individuals.
Methods: This study was an observational study comprising of voglibose and placebo in individuals with impaired glucose tolerance.60 eligible patients were on the standard diet and taking regular exercise with impaired glucose tolerance were randomly assigned to oral voglibose 0.2 mg three times a day (n=60) or placebo (n=50) in this study. Treatment was continued until participants developed type 2 diabetes (primary endpoint) or normoglycaemia (secondary endpoint). In the final analysis, 60 registered individuals fulfilled the inclusion criteria: 36 were randomly assigned to receive voglibose and 24 placebos (two participants in the placebo group did not take their medication and were excluded). The mean duration of treatment was 48•4 weeks (SD 36•5)—i.e., 45•3 weeks (34•6) for voglibose and 51•6 weeks (37•5) for placebo.
Conclusion: Voglibose, in addition to lifestyle modification, can reduce the development of type 2 diabetes in high risk individuals with impaired glucose tolerance.